factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fact | preserve | 993-995 | 993-995 | T55 | in | TREATS | 993 | 995 | preserve | 964-978 | 968-978 | T46 | ACE inhibitors | PharmacologicSubstance | 964 | 978 | preserve | 1028-1047 | 1040-1047 | T50 | heart failure | DiseaseOrSyndrome | 1,028 | 1,047 | A16 | Currently, the use of digoxin can be advocated to control heart failure in atrial fibrillation and when added to ACE inhibitors and diuretics in those patients with symptomatic heart failure related to systolic left ventricular dysfunction. | 839-1097 | 839 | 1,097 | Currently, the use of digoxin can be advocated to control heart failure in atrial fibrillation and when added to @SUBJECT$ and diuretics @PREDICAT$ those patients with symptomatic @OBJECT$ related to systolic left ventricular dysfunction. |
Fact | preserve | 993-995 | 993-995 | T55 | in | TREATS | 993 | 995 | preserve | 983-992 | 983-992 | T47 | diuretics | PharmacologicSubstance | 983 | 992 | preserve | 1002-1010 | 1002-1010 | T48 | patients | PatientOrDisabledGroup | 1,002 | 1,010 | A17 | Currently, the use of digoxin can be advocated to control heart failure in atrial fibrillation and when added to ACE inhibitors and diuretics in those patients with symptomatic heart failure related to systolic left ventricular dysfunction. | 839-1097 | 839 | 1,097 | Currently, the use of digoxin can be advocated to control heart failure in atrial fibrillation and when added to ACE inhibitors and @SUBJECT$ @PREDICAT$ those @OBJECT$ with symptomatic heart failure related to systolic left ventricular dysfunction. |
Fact | preserve | 1978-2018 | 1986-1990 | T107 | disease such as critical aortic stenosis | LOCATION_OF | 1,978 | 2,018 | preserve | 1969-1977 | 1969-1977 | T98 | valvular | BodyPartOrganOrOrganComponent | 1,969 | 1,977 | preserve | 2003-2018 | 2010-2018 | T101 | aortic stenosis | DiseaseOrSyndrome | 2,003 | 2,018 | A19 | This simple diagnostic tool, along with a careful history and medical examination, would hopefully prevent the misinterpretation of confusing clinical findings and would help to identify the patients with normal systolic function or valvular disease such as critical aortic stenosis, where digoxin treatment would not be warranted. | 1716-2074 | 1,716 | 2,074 | This simple diagnostic tool, along with a careful history and medical examination, would hopefully prevent the misinterpretation of confusing clinical findings and would help to identify the patients with normal systolic function or @SUBJECT$ @PREDICAT$ @OBJECT$ , where digoxin treatment would not be warranted. |
Fact | preserve | 2159-2163 | 2159-2163 | T127 | with | PROCESS_OF | 2,159 | 2,163 | preserve | 2185-2191 | 2185-2191 | T121 | asthma | DiseaseOrSyndrome | 2,185 | 2,191 | preserve | 2150-2158 | 2150-2158 | T118 | Patients | PatientOrDisabledGroup | 2,150 | 2,158 | A2 | Patients with difficult-to-control asthma may develop exacerbations despite treatment with inhaled corticosteroids, which appear to have an eosinophil-independent mechanism. | 2150-2335 | 2,150 | 2,335 | @OBJECT$ @PREDICAT$ difficult-to-control @SUBJECT$ may develop exacerbations despite treatment with inhaled corticosteroids, which appear to have an eosinophil-independent mechanism. |
Fact | preserve | 1750-1774 | 1765-1774 | T93 | corticosteroid treatment | USES | 1,750 | 1,774 | preserve | 1750-1764 | 1750-1764 | T89 | corticosteroid | Hormone | 1,750 | 1,764 | preserve | 1750-1764 | 1750-1764 | T89 | corticosteroid | Hormone | 1,750 | 1,764 | A3 | Patients with difficult-to-control asthma had more exacerbations than did the stable asthmatics during both steroid tapering (7 versus 2; p = 0.022) and corticosteroid treatment (6 versus 0; p = 0.003). | 1585-1799 | 1,585 | 1,799 | Patients with difficult-to-control asthma had more exacerbations than did the stable asthmatics during both steroid tapering (7 versus 2; p = 0.022) and @OBJECT$ @SUBJECT$ @PREDICAT$ (6 versus 0; p = 0.003). |
Fact | preserve | 1839-1841 | 1839-1841 | T107 | in | TREATS | 1,839 | 1,841 | preserve | 1821-1838 | 1829-1838 | T95 | steroid treatment | TherapeuticOrPreventiveProcedure | 1,821 | 1,838 | preserve | 1846-1854 | 1846-1854 | T96 | patients | PatientOrDisabledGroup | 1,846 | 1,854 | A4 | Exacerbations during steroid treatment in the patients with difficult-to-control asthma were associated with a decrease in FEV1 and PC20MCh, but not in HYP slope or increase in sputum eosinophils. | 1800-2010 | 1,800 | 2,010 | Exacerbations during @SUBJECT$ @PREDICAT$ the @OBJECT$ with difficult-to-control asthma were associated with a decrease in FEV1 and PC20MCh, but not in HYP slope or increase in sputum eosinophils. |
Fact | preserve | 1594-1598 | 1594-1598 | T92 | with | PROCESS_OF | 1,594 | 1,598 | preserve | 1620-1626 | 1620-1626 | T84 | asthma | DiseaseOrSyndrome | 1,620 | 1,626 | preserve | 1585-1593 | 1585-1593 | T81 | Patients | PatientOrDisabledGroup | 1,585 | 1,593 | A8 | Patients with difficult-to-control asthma had more exacerbations than did the stable asthmatics during both steroid tapering (7 versus 2; p = 0.022) and corticosteroid treatment (6 versus 0; p = 0.003). | 1585-1799 | 1,585 | 1,799 | @OBJECT$ @PREDICAT$ difficult-to-control @SUBJECT$ had more exacerbations than did the stable asthmatics during both steroid tapering (7 versus 2; p = 0.022) and corticosteroid treatment (6 versus 0; p = 0.003). |
Fact | preserve | 159-163 | 159-163 | T16 | with | PROCESS_OF | 159 | 163 | preserve | 164-177 | 171-177 | T11 | severe asthma | Finding | 164 | 177 | preserve | 150-158 | 150-158 | T10 | patients | PatientOrDisabledGroup | 150 | 158 | A9 | Some patients with severe asthma are difficult to control and suffer from frequent exacerbations, whereas others remain stable with anti-inflammatory therapy. | 145-315 | 145 | 315 | Some @OBJECT$ @PREDICAT$ @SUBJECT$ are difficult to control and suffer from frequent exacerbations, whereas others remain stable with anti-inflammatory therapy. |
Fact | preserve | 1839-1841 | 1839-1841 | T107 | in | TREATS | 1,839 | 1,841 | preserve | 1821-1838 | 1829-1838 | T95 | steroid treatment | TherapeuticOrPreventiveProcedure | 1,821 | 1,838 | preserve | 1888-1894 | 1888-1894 | T99 | asthma | DiseaseOrSyndrome | 1,888 | 1,894 | A10 | Exacerbations during steroid treatment in the patients with difficult-to-control asthma were associated with a decrease in FEV1 and PC20MCh, but not in HYP slope or increase in sputum eosinophils. | 1800-2010 | 1,800 | 2,010 | Exacerbations during @SUBJECT$ @PREDICAT$ the patients with difficult-to-control @OBJECT$ were associated with a decrease in FEV1 and PC20MCh, but not in HYP slope or increase in sputum eosinophils. |
Fact | preserve | 53-57 | 53-57 | T9 | with | PROCESS_OF | 53 | 57 | preserve | 58-71 | 65-71 | T5 | severe asthma | Finding | 58 | 71 | preserve | 44-52 | 44-52 | T4 | patients | PatientOrDisabledGroup | 44 | 52 | A11 | Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal. | 0-144 | 0 | 144 | Lung function and sputum characteristics of @OBJECT$ @PREDICAT$ @SUBJECT$ during an induced exacerbation by double-blind steroid withdrawal. |
Fact | preserve | 818-857 | 847-857 | T48 | corticosteroids (fluticasone propionate | ISA | 818 | 857 | preserve | 835-857 | 847-857 | T45 | fluticasone propionate | OrganicChemical | 835 | 857 | preserve | 818-833 | 818-833 | T44 | corticosteroids | Hormone | 818 | 833 | A13 | Exacerbations were induced by double-blind, controlled tapering of inhaled corticosteroids (fluticasone propionate) at weekly intervals. | 737-879 | 737 | 879 | Exacerbations were induced by double-blind, controlled tapering of inhaled @OBJECT$ @PREDICAT$ @SUBJECT$ ) at weekly intervals. |
Fact | preserve | 1855-1859 | 1855-1859 | T108 | with | PROCESS_OF | 1,855 | 1,859 | preserve | 1888-1894 | 1888-1894 | T99 | asthma | DiseaseOrSyndrome | 1,888 | 1,894 | preserve | 1846-1854 | 1846-1854 | T96 | patients | PatientOrDisabledGroup | 1,846 | 1,854 | A14 | Exacerbations during steroid treatment in the patients with difficult-to-control asthma were associated with a decrease in FEV1 and PC20MCh, but not in HYP slope or increase in sputum eosinophils. | 1800-2010 | 1,800 | 2,010 | Exacerbations during steroid treatment in the @OBJECT$ @PREDICAT$ difficult-to-control @SUBJECT$ were associated with a decrease in FEV1 and PC20MCh, but not in HYP slope or increase in sputum eosinophils. |
Fact | preserve | 1750-1774 | 1765-1774 | T91 | corticosteroid treatment | ISA | 1,750 | 1,774 | preserve | 1750-1764 | 1750-1764 | T89 | corticosteroid | Hormone | 1,750 | 1,764 | preserve | 1765-1774 | 1765-1774 | T90 | treatment | TherapeuticOrPreventiveProcedure | 1,765 | 1,774 | A15 | Patients with difficult-to-control asthma had more exacerbations than did the stable asthmatics during both steroid tapering (7 versus 2; p = 0.022) and corticosteroid treatment (6 versus 0; p = 0.003). | 1585-1799 | 1,585 | 1,799 | Patients with difficult-to-control asthma had more exacerbations than did the stable asthmatics during both steroid tapering (7 versus 2; p = 0.022) and @SUBJECT$ @PREDICAT$ @OBJECT$ (6 versus 0; p = 0.003). |
Fact | preserve | 234-243 | 234-243 | T22 | treatment | TREATS | 234 | 243 | preserve | 184-215 | 205-215 | T16 | leukotriene receptor antagonist | OrganicChemical | 184 | 215 | preserve | 278-284 | 278-284 | T20 | asthma | DiseaseOrSyndrome | 278 | 284 | A3 | BACKGROUND: Zafirlukast is an oral leukotriene receptor antagonist used in the treatment of patients with mild to moderate asthma. | 149-285 | 149 | 285 | BACKGROUND: Zafirlukast is an oral @SUBJECT$ used in the @PREDICAT$ of patients with mild to moderate @OBJECT$ . |
Fact | preserve | 423-426 | 423-426 | T40 | had | PROCESS_OF | 423 | 426 | preserve | 427-433 | 427-433 | T34 | asthma | DiseaseOrSyndrome | 427 | 433 | preserve | 410-418 | 410-418 | T33 | patients | PatientOrDisabledGroup | 410 | 418 | A4 | To investigate its effects in a clinical practice setting, we evaluated zafirlukast in a heterogeneous group of patients who had asthma of different degrees of severity and who were receiving concomitant asthma medications. | 286-527 | 286 | 527 | To investigate its effects in a clinical practice setting, we evaluated zafirlukast in a heterogeneous group of @OBJECT$ who @PREDICAT$ @SUBJECT$ of different degrees of severity and who were receiving concomitant asthma medications. |
Fact | preserve | 161-215 | 205-215 | T21 | Zafirlukast is an oral leukotriene receptor antagonist | ISA | 161 | 215 | preserve | 161-172 | 161-172 | T14 | Zafirlukast | OrganicChemical | 161 | 172 | preserve | 184-215 | 205-215 | T16 | leukotriene receptor antagonist | OrganicChemical | 184 | 215 | A7 | BACKGROUND: Zafirlukast is an oral leukotriene receptor antagonist used in the treatment of patients with mild to moderate asthma. | 149-285 | 149 | 285 | BACKGROUND: @SUBJECT$ @PREDICAT$ @OBJECT$ used in the treatment of patients with mild to moderate asthma. |
Fact | preserve | 161-215 | 205-215 | T24 | Zafirlukast is an oral leukotriene receptor antagonist | TREATS | 161 | 215 | preserve | 161-172 | 161-172 | T14 | Zafirlukast | OrganicChemical | 161 | 172 | preserve | 247-255 | 247-255 | T18 | patients | PatientOrDisabledGroup | 247 | 255 | A9 | BACKGROUND: Zafirlukast is an oral leukotriene receptor antagonist used in the treatment of patients with mild to moderate asthma. | 149-285 | 149 | 285 | BACKGROUND: @SUBJECT$ @PREDICAT$ used in the treatment of @OBJECT$ with mild to moderate asthma. |
Fact | preserve | 256-260 | 256-260 | T23 | with | PROCESS_OF | 256 | 260 | preserve | 278-284 | 278-284 | T20 | asthma | DiseaseOrSyndrome | 278 | 284 | preserve | 247-255 | 247-255 | T18 | patients | PatientOrDisabledGroup | 247 | 255 | A10 | BACKGROUND: Zafirlukast is an oral leukotriene receptor antagonist used in the treatment of patients with mild to moderate asthma. | 149-285 | 149 | 285 | BACKGROUND: Zafirlukast is an oral leukotriene receptor antagonist used in the treatment of @OBJECT$ @PREDICAT$ mild to moderate @SUBJECT$ . |
Fact | preserve | 136-140 | 136-140 | T12 | with | PROCESS_OF | 136 | 140 | preserve | 141-147 | 141-147 | T10 | asthma | DiseaseOrSyndrome | 141 | 147 | preserve | 127-135 | 127-135 | T9 | patients | PatientOrDisabledGroup | 127 | 135 | A11 | Zafirlukast in clinical practice: results of the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT) in patients with asthma. | 0-148 | 0 | 148 | Zafirlukast in clinical practice: results of the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT) in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1080-1083 | 1080-1083 | T84 | had | PROCESS_OF | 1,080 | 1,083 | preserve | 1093-1111 | 1103-1111 | T79 | pulmonary function | OrganOrTissueFunction | 1,093 | 1,111 | preserve | 1065-1073 | 1065-1073 | T77 | patients | PatientOrDisabledGroup | 1,065 | 1,073 | A13 | A total of 71% of patients had improved pulmonary function and 72% had improved asthma symptoms. | 1047-1149 | 1,047 | 1,149 | A total of 71% of @OBJECT$ @PREDICAT$ improved @SUBJECT$ and 72% had improved asthma symptoms. |
Uncommitted | preserve | 124-126 | 124-126 | T11 | in | TREATS | 124 | 126 | preserve | 0-11 | 0-11 | T1 | Zafirlukast | OrganicChemical | 0 | 11 | preserve | 127-135 | 127-135 | T9 | patients | PatientOrDisabledGroup | 127 | 135 | A14 | Zafirlukast in clinical practice: results of the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT) in patients with asthma. | 0-148 | 0 | 148 | @SUBJECT$ in clinical practice: results of the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT) @PREDICAT$ @OBJECT$ with asthma. |
Uncommitted | preserve | 124-126 | 124-126 | T11 | in | TREATS | 124 | 126 | preserve | 0-11 | 0-11 | T1 | Zafirlukast | OrganicChemical | 0 | 11 | preserve | 141-147 | 141-147 | T10 | asthma | DiseaseOrSyndrome | 141 | 147 | A15 | Zafirlukast in clinical practice: results of the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT) in patients with asthma. | 0-148 | 0 | 148 | @SUBJECT$ in clinical practice: results of the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT) @PREDICAT$ patients with @OBJECT$ . |
Fact | preserve | 480-489 | 480-489 | T41 | receiving | ADMINISTERED_TO | 480 | 489 | preserve | 515-526 | 515-526 | T39 | medications | PharmacologicSubstance | 515 | 526 | preserve | 410-418 | 410-418 | T33 | patients | PatientOrDisabledGroup | 410 | 418 | A16 | To investigate its effects in a clinical practice setting, we evaluated zafirlukast in a heterogeneous group of patients who had asthma of different degrees of severity and who were receiving concomitant asthma medications. | 286-527 | 286 | 527 | To investigate its effects in a clinical practice setting, we evaluated zafirlukast in a heterogeneous group of @OBJECT$ who had asthma of different degrees of severity and who were @PREDICAT$ concomitant asthma @SUBJECT$ . |
Fact | preserve | 234-243 | 234-243 | T22 | treatment | TREATS | 234 | 243 | preserve | 184-215 | 205-215 | T16 | leukotriene receptor antagonist | OrganicChemical | 184 | 215 | preserve | 247-255 | 247-255 | T18 | patients | PatientOrDisabledGroup | 247 | 255 | A17 | BACKGROUND: Zafirlukast is an oral leukotriene receptor antagonist used in the treatment of patients with mild to moderate asthma. | 149-285 | 149 | 285 | BACKGROUND: Zafirlukast is an oral @SUBJECT$ used in the @PREDICAT$ of @OBJECT$ with mild to moderate asthma. |
Fact | preserve | 1633-1646 | 1640-1646 | T97 | labial herpes | LOCATION_OF | 1,633 | 1,646 | preserve | 1633-1639 | 1633-1639 | T93 | labial | BodyLocationOrRegion | 1,633 | 1,639 | preserve | 1640-1646 | 1640-1646 | T94 | herpes | DiseaseOrSyndrome | 1,640 | 1,646 | A1 | No secondary effects were observed with the exception of a labial herpes in the pediatric patient. | 1574-1678 | 1,574 | 1,678 | No secondary effects were observed with the exception of a @SUBJECT$ @PREDICAT$ @OBJECT$ in the pediatric patient. |
Fact | preserve | 1647-1649 | 1647-1649 | T98 | in | PROCESS_OF | 1,647 | 1,649 | preserve | 1640-1646 | 1640-1646 | T94 | herpes | DiseaseOrSyndrome | 1,640 | 1,646 | preserve | 1670-1677 | 1670-1677 | T96 | patient | PatientOrDisabledGroup | 1,670 | 1,677 | A2 | No secondary effects were observed with the exception of a labial herpes in the pediatric patient. | 1574-1678 | 1,574 | 1,678 | No secondary effects were observed with the exception of a labial @SUBJECT$ @PREDICAT$ the pediatric @OBJECT$ . |
Fact | preserve | 1925-1929 | 1925-1929 | T118 | with | PROCESS_OF | 1,925 | 1,929 | preserve | 1955-1971 | 1965-1971 | T114 | bronchial asthma | DiseaseOrSyndrome | 1,955 | 1,971 | preserve | 1916-1924 | 1916-1924 | T112 | patients | PatientOrDisabledGroup | 1,916 | 1,924 | A3 | CONCLUSIONS: The administration of one single weekly dose of methotrexate 10 mg in adults and 15 in one pediatric patient allowed for a decrease of approximately 50% in the glucocorticosteroid dosage in this group of patients with corticosteroid-dependent bronchial asthma with no relevant adverse reactions during therapy. | 1679-2029 | 1,679 | 2,029 | CONCLUSIONS: The administration of one single weekly dose of methotrexate 10 mg in adults and 15 in one pediatric patient allowed for a decrease of approximately 50% in the glucocorticosteroid dosage in this group of @OBJECT$ @PREDICAT$ corticosteroid-dependent @SUBJECT$ with no relevant adverse reactions during therapy. |
Fact | preserve | 524-528 | 524-528 | T37 | with | USES | 524 | 528 | preserve | 514-523 | 514-523 | T34 | treatment | TherapeuticOrPreventiveProcedure | 514 | 523 | preserve | 529-532 | 529-532 | T35 | MTX | OrganicChemical | 529 | 532 | A4 | The minimal stabilization time for each patient before initiating treatment with MTX was 3 months. | 442-546 | 442 | 546 | The minimal stabilization time for each patient before initiating @SUBJECT$ @PREDICAT$ @OBJECT$ was 3 months. |
Fact | preserve | 1524-1528 | 1524-1528 | T89 | with | USES | 1,524 | 1,528 | preserve | 1514-1523 | 1514-1523 | T85 | treatment | TherapeuticOrPreventiveProcedure | 1,514 | 1,523 | preserve | 1529-1541 | 1529-1541 | T86 | methotrexate | OrganicChemical | 1,529 | 1,541 | A5 | In all patients a significant decrease could be obtained in the MP dose during treatment with methotrexate with no decrease in FEV1. | 1428-1573 | 1,428 | 1,573 | In all patients a significant decrease could be obtained in the MP dose during @SUBJECT$ @PREDICAT$ @OBJECT$ with no decrease in FEV1. |
Fact | preserve | 1409-1413 | 1409-1413 | T80 | with | USES | 1,409 | 1,413 | preserve | 1399-1408 | 1399-1408 | T78 | treatment | TherapeuticOrPreventiveProcedure | 1,399 | 1,408 | preserve | 1414-1426 | 1414-1426 | T79 | methotrexate | OrganicChemical | 1,414 | 1,426 | A6 | In the pediatric patient, the deflazacor dose was decreased from 60 down to 30 mg/day during treatment with methotrexate. | 1294-1427 | 1,294 | 1,427 | In the pediatric patient, the deflazacor dose was decreased from 60 down to 30 mg/day during @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 198-200 | 198-200 | T16 | in | TREATS | 198 | 200 | preserve | 147-159 | 147-159 | T8 | methotrexate | OrganicChemical | 147 | 159 | preserve | 211-219 | 211-219 | T12 | patients | PatientOrDisabledGroup | 211 | 219 | A7 | OBJECTIVE: To evaluate the efficiency of low doses of methotrexate as corticosteroid sparing agent in asthmatic patients requiring long term corticosteroid therapy. | 93-269 | 93 | 269 | OBJECTIVE: To evaluate the efficiency of low doses of @SUBJECT$ as corticosteroid sparing agent @PREDICAT$ asthmatic @OBJECT$ requiring long term corticosteroid therapy. |
Counterfact | preserve | 1972-1976 | 1972-1976 | T119 | with | PROCESS_OF | 1,972 | 1,976 | preserve | 1989-2013 | 2004-2013 | T115 | adverse reactions | Finding | 1,989 | 2,013 | preserve | 1916-1924 | 1916-1924 | T112 | patients | PatientOrDisabledGroup | 1,916 | 1,924 | A8 | CONCLUSIONS: The administration of one single weekly dose of methotrexate 10 mg in adults and 15 in one pediatric patient allowed for a decrease of approximately 50% in the glucocorticosteroid dosage in this group of patients with corticosteroid-dependent bronchial asthma with no relevant adverse reactions during therapy. | 1679-2029 | 1,679 | 2,029 | CONCLUSIONS: The administration of one single weekly dose of methotrexate 10 mg in adults and 15 in one pediatric patient allowed for a decrease of approximately 50% in the glucocorticosteroid dosage in this group of @OBJECT$ with corticosteroid-dependent bronchial asthma @PREDICAT$ no relevant @SUBJECT$ during therapy. |
Fact | preserve | 201-219 | 211-219 | T15 | asthmatic patients | PROCESS_OF | 201 | 219 | preserve | 201-210 | 201-210 | T11 | asthmatic | DiseaseOrSyndrome | 201 | 210 | preserve | 211-219 | 211-219 | T12 | patients | PatientOrDisabledGroup | 211 | 219 | A9 | OBJECTIVE: To evaluate the efficiency of low doses of methotrexate as corticosteroid sparing agent in asthmatic patients requiring long term corticosteroid therapy. | 93-269 | 93 | 269 | OBJECTIVE: To evaluate the efficiency of low doses of methotrexate as corticosteroid sparing agent in @SUBJECT$ @PREDICAT$ @OBJECT$ requiring long term corticosteroid therapy. |
Fact | preserve | 198-200 | 198-200 | T16 | in | TREATS | 198 | 200 | preserve | 147-159 | 147-159 | T8 | methotrexate | OrganicChemical | 147 | 159 | preserve | 201-210 | 201-210 | T11 | asthmatic | DiseaseOrSyndrome | 201 | 210 | A10 | OBJECTIVE: To evaluate the efficiency of low doses of methotrexate as corticosteroid sparing agent in asthmatic patients requiring long term corticosteroid therapy. | 93-269 | 93 | 269 | OBJECTIVE: To evaluate the efficiency of low doses of @SUBJECT$ as corticosteroid sparing agent @PREDICAT$ @OBJECT$ patients requiring long term corticosteroid therapy. |
Fact | preserve | 1766-1768 | 1766-1768 | T117 | in | TREATS | 1,766 | 1,768 | preserve | 1747-1765 | 1763-1765 | T103 | methotrexate 10 mg | ClinicalDrug | 1,747 | 1,765 | preserve | 1769-1775 | 1769-1775 | T104 | adults | AgeGroup | 1,769 | 1,775 | A11 | CONCLUSIONS: The administration of one single weekly dose of methotrexate 10 mg in adults and 15 in one pediatric patient allowed for a decrease of approximately 50% in the glucocorticosteroid dosage in this group of patients with corticosteroid-dependent bronchial asthma with no relevant adverse reactions during therapy. | 1679-2029 | 1,679 | 2,029 | CONCLUSIONS: The administration of one single weekly dose of @SUBJECT$ @PREDICAT$ @OBJECT$ and 15 in one pediatric patient allowed for a decrease of approximately 50% in the glucocorticosteroid dosage in this group of patients with corticosteroid-dependent bronchial asthma with no relevant adverse reactions during therapy. |
Fact | preserve | 2828-2844 | 2837-2844 | T160 | levodopa therapy | ISA | 2,828 | 2,844 | preserve | 2828-2836 | 2828-2836 | T147 | levodopa | AminoAcidPeptideOrProtein | 2,828 | 2,836 | preserve | 2837-2844 | 2837-2844 | T148 | therapy | TherapeuticOrPreventiveProcedure | 2,837 | 2,844 | A1 | Indeed, levodopa therapy improves, sometimes markedly, the motor signs and symptoms of the illness, the functional capacity and quality of life and perhaps also life expectancy of the afflicted patients. | 2820-3035 | 2,820 | 3,035 | Indeed, @SUBJECT$ @PREDICAT$ @OBJECT$ improves, sometimes markedly, the motor signs and symptoms of the illness, the functional capacity and quality of life and perhaps also life expectancy of the afflicted patients. |
Probable | preserve | 2170-2178 | 2170-2178 | T125 | combined | COEXISTS_WITH | 2,170 | 2,178 | preserve | 2195-2230 | 2220-2230 | T119 | dopa decarboxylase inhibitors | OrganicChemical | 2,195 | 2,230 | preserve | 2125-2133 | 2125-2133 | T117 | Levodopa | AminoAcidPeptideOrProtein | 2,125 | 2,133 | A2 | Levodopa, administered orally, usually combined with peripheral dopa decarboxylase inhibitors, continues to be the most widely-used and most effective pharmacological treatment for Parkinson's disease (Melamed, 1987). | 2125-2360 | 2,125 | 2,360 | @OBJECT$ , administered orally, usually @PREDICAT$ with peripheral @SUBJECT$ , continues to be the most widely-used and most effective pharmacological treatment for Parkinson's disease (Melamed, 1987). |
Fact | preserve | 3684-3700 | 3693-3700 | T196 | levodopa therapy | USES | 3,684 | 3,700 | preserve | 3684-3692 | 3684-3692 | T188 | levodopa | AminoAcidPeptideOrProtein | 3,684 | 3,692 | preserve | 3684-3692 | 3684-3692 | T188 | levodopa | AminoAcidPeptideOrProtein | 3,684 | 3,692 | A3 | It is believed that most patients on long-term levodopa therapy will, sooner or later, develop response fluctuations of varying types and severity (Riley and Lang, 1993). | 3637-3820 | 3,637 | 3,820 | It is believed that most patients on long-term @OBJECT$ @SUBJECT$ @PREDICAT$ will, sooner or later, develop response fluctuations of varying types and severity (Riley and Lang, 1993). |
Fact | preserve | 1338-1361 | 1344-1348 | T80 | drugs such as prepulsid | ISA | 1,338 | 1,361 | preserve | 1352-1361 | 1352-1361 | T76 | prepulsid | OrganicChemical | 1,352 | 1,361 | preserve | 1338-1343 | 1338-1343 | T75 | drugs | PharmacologicSubstance | 1,338 | 1,343 | A4 | Prokinetic drugs such as prepulsid (Cisaprid) could be used to facilitate gastric motility and levodopa transit time. | 1327-1450 | 1,327 | 1,450 | Prokinetic @OBJECT$ @PREDICAT$ @SUBJECT$ (Cisaprid) could be used to facilitate gastric motility and levodopa transit time. |
Fact | preserve | 2828-2844 | 2837-2844 | T161 | levodopa therapy | USES | 2,828 | 2,844 | preserve | 2828-2836 | 2828-2836 | T147 | levodopa | AminoAcidPeptideOrProtein | 2,828 | 2,836 | preserve | 2828-2836 | 2828-2836 | T147 | levodopa | AminoAcidPeptideOrProtein | 2,828 | 2,836 | A5 | Indeed, levodopa therapy improves, sometimes markedly, the motor signs and symptoms of the illness, the functional capacity and quality of life and perhaps also life expectancy of the afflicted patients. | 2820-3035 | 2,820 | 3,035 | Indeed, @OBJECT$ @SUBJECT$ @PREDICAT$ improves, sometimes markedly, the motor signs and symptoms of the illness, the functional capacity and quality of life and perhaps also life expectancy of the afflicted patients. |
Possible | preserve | 1396-1406 | 1396-1406 | T81 | facilitate | AUGMENTS | 1,396 | 1,406 | preserve | 1352-1361 | 1352-1361 | T76 | prepulsid | OrganicChemical | 1,352 | 1,361 | preserve | 1407-1423 | 1415-1423 | T77 | gastric motility | OrganOrTissueFunction | 1,407 | 1,423 | A6 | Prokinetic drugs such as prepulsid (Cisaprid) could be used to facilitate gastric motility and levodopa transit time. | 1327-1450 | 1,327 | 1,450 | Prokinetic drugs such as @SUBJECT$ (Cisaprid) could be used to @PREDICAT$ @OBJECT$ and levodopa transit time. |
Fact | preserve | 3684-3700 | 3693-3700 | T195 | levodopa therapy | ISA | 3,684 | 3,700 | preserve | 3684-3692 | 3684-3692 | T188 | levodopa | AminoAcidPeptideOrProtein | 3,684 | 3,692 | preserve | 3693-3700 | 3693-3700 | T189 | therapy | TherapeuticOrPreventiveProcedure | 3,693 | 3,700 | A9 | It is believed that most patients on long-term levodopa therapy will, sooner or later, develop response fluctuations of varying types and severity (Riley and Lang, 1993). | 3637-3820 | 3,637 | 3,820 | It is believed that most patients on long-term @SUBJECT$ @PREDICAT$ @OBJECT$ will, sooner or later, develop response fluctuations of varying types and severity (Riley and Lang, 1993). |
Fact | preserve | 53-57 | 53-57 | T10 | with | PROCESS_OF | 53 | 57 | preserve | 58-92 | 85-92 | T7 | advanced Parkinson's disease | Finding | 58 | 92 | preserve | 44-52 | 44-52 | T5 | patients | PatientOrDisabledGroup | 44 | 52 | A12 | Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa. | 0-127 | 0 | 127 | Current management of motor fluctuations in @OBJECT$ @PREDICAT$ @SUBJECT$ treated chronically with levodopa. |
Probable | preserve | 3731-3738 | 3731-3738 | T197 | develop | PROCESS_OF | 3,731 | 3,738 | preserve | 3748-3760 | 3748-3760 | T191 | fluctuations | SignOrSymptom | 3,748 | 3,760 | preserve | 3662-3670 | 3662-3670 | T186 | patients | PatientOrDisabledGroup | 3,662 | 3,670 | A13 | It is believed that most patients on long-term levodopa therapy will, sooner or later, develop response fluctuations of varying types and severity (Riley and Lang, 1993). | 3637-3820 | 3,637 | 3,820 | It is believed that most @OBJECT$ on long-term levodopa therapy will, sooner or later, @PREDICAT$ response @SUBJECT$ of varying types and severity (Riley and Lang, 1993). |
Fact | preserve | 41-43 | 41-43 | T9 | in | PROCESS_OF | 41 | 43 | preserve | 28-40 | 28-40 | T4 | fluctuations | SignOrSymptom | 28 | 40 | preserve | 44-52 | 44-52 | T5 | patients | PatientOrDisabledGroup | 44 | 52 | A15 | Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa. | 0-127 | 0 | 127 | Current management of motor @SUBJECT$ @PREDICAT$ @OBJECT$ with advanced Parkinson's disease treated chronically with levodopa. |
Fact | preserve | 2320-2323 | 2320-2323 | T126 | for | TREATS | 2,320 | 2,323 | preserve | 2294-2319 | 2310-2319 | T123 | pharmacological treatment | TherapeuticOrPreventiveProcedure | 2,294 | 2,319 | preserve | 2324-2343 | 2336-2343 | T124 | Parkinson's disease | DiseaseOrSyndrome | 2,324 | 2,343 | A16 | Levodopa, administered orally, usually combined with peripheral dopa decarboxylase inhibitors, continues to be the most widely-used and most effective pharmacological treatment for Parkinson's disease (Melamed, 1987). | 2125-2360 | 2,125 | 2,360 | Levodopa, administered orally, usually combined with peripheral dopa decarboxylase inhibitors, continues to be the most widely-used and most effective @SUBJECT$ @PREDICAT$ @OBJECT$ (Melamed, 1987). |
Fact | preserve | 93-100 | 93-100 | T11 | treated | TREATS | 93 | 100 | preserve | 118-126 | 118-126 | T8 | levodopa | AminoAcidPeptideOrProtein | 118 | 126 | preserve | 58-92 | 85-92 | T7 | advanced Parkinson's disease | Finding | 58 | 92 | A17 | Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa. | 0-127 | 0 | 127 | Current management of motor fluctuations in patients with @OBJECT$ @PREDICAT$ chronically with @SUBJECT$ . |
Fact | preserve | 795-797 | 795-797 | T51 | in | PROCESS_OF | 795 | 797 | preserve | 778-794 | 786-794 | T49 | gastric emptying | OrganOrTissueFunction | 778 | 794 | preserve | 818-826 | 818-826 | T50 | patients | PatientOrDisabledGroup | 818 | 826 | A19 | In addition, there is delayed gastric emptying in many advanced patients. | 748-827 | 748 | 827 | In addition, there is delayed @SUBJECT$ @PREDICAT$ many advanced @OBJECT$ . |
Fact | preserve | 1732-1736 | 1732-1736 | T109 | used | ADMINISTERED_TO | 1,732 | 1,736 | preserve | 1755-1764 | 1755-1764 | T99 | therapies | TherapeuticOrPreventiveProcedure | 1,755 | 1,764 | preserve | 1719-1727 | 1719-1727 | T98 | patients | PatientOrDisabledGroup | 1,719 | 1,727 | A4 | Data from studies of patients who used their usual therapies and sumatriptan in nonblinded, sequential phases indicate that both workplace and nonworkplace productivity losses were reduced during sumatriptan therapy. | 1698-1932 | 1,698 | 1,932 | Data from studies of @OBJECT$ who @PREDICAT$ their usual @SUBJECT$ and sumatriptan in nonblinded, sequential phases indicate that both workplace and nonworkplace productivity losses were reduced during sumatriptan therapy. |
Fact | preserve | 1732-1736 | 1732-1736 | T109 | used | ADMINISTERED_TO | 1,732 | 1,736 | preserve | 1769-1780 | 1769-1780 | T100 | sumatriptan | OrganicChemical | 1,769 | 1,780 | preserve | 1719-1727 | 1719-1727 | T98 | patients | PatientOrDisabledGroup | 1,719 | 1,727 | A5 | Data from studies of patients who used their usual therapies and sumatriptan in nonblinded, sequential phases indicate that both workplace and nonworkplace productivity losses were reduced during sumatriptan therapy. | 1698-1932 | 1,698 | 1,932 | Data from studies of @OBJECT$ who @PREDICAT$ their usual therapies and @SUBJECT$ in nonblinded, sequential phases indicate that both workplace and nonworkplace productivity losses were reduced during sumatriptan therapy. |
Fact | preserve | 906-915 | 906-915 | T51 | treatment | TREATS | 906 | 915 | preserve | 840-851 | 840-851 | T44 | Sumatriptan | OrganicChemical | 840 | 851 | preserve | 919-927 | 919-927 | T49 | migraine | DiseaseOrSyndrome | 919 | 927 | A8 | Sumatriptan is an effective and well tolerated agent in the treatment of migraine. | 840-928 | 840 | 928 | @SUBJECT$ is an effective and well tolerated agent in the @PREDICAT$ of @OBJECT$ . |
Fact | preserve | 3145-3149 | 3145-3149 | T178 | with | PROCESS_OF | 3,145 | 3,149 | preserve | 3156-3164 | 3156-3164 | T176 | migraine | DiseaseOrSyndrome | 3,156 | 3,164 | preserve | 3136-3144 | 3136-3144 | T175 | patients | PatientOrDisabledGroup | 3,136 | 3,144 | A9 | Thus, sumatriptan is associated with a fast onset of action and improvements in health-related quality of life in patients with migraine. | 3016-3165 | 3,016 | 3,165 | Thus, sumatriptan is associated with a fast onset of action and improvements in health-related quality of life in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 711-725 | 716-725 | T43 | drug treatment | USES | 711 | 725 | preserve | 716-725 | 716-725 | T37 | treatment | TherapeuticOrPreventiveProcedure | 716 | 725 | preserve | 711-715 | 711-715 | T36 | drug | PharmacologicSubstance | 711 | 715 | A12 | Direct costs, such as the cost of drug treatment, physician consultation, hospitalisation and emergency room treatment, make up most of the remainder. | 677-839 | 677 | 839 | Direct costs, such as the cost of @OBJECT$ @PREDICAT$ @SUBJECT$ , physician consultation, hospitalisation and emergency room treatment, make up most of the remainder. |
Fact | preserve | 2456-2462 | 2456-2462 | T143 | versus | compared_with | 2,456 | 2,462 | preserve | 2444-2455 | 2444-2455 | T137 | sumatriptan | OrganicChemical | 2,444 | 2,455 | preserve | 2482-2499 | 2482-2499 | T139 | dihydroergotamine | OrganicChemical | 2,482 | 2,499 | A15 | A retrospective pharmacoeconomic model suggested that the cost-effectiveness of subcutaneous sumatriptan versus subcutaneous dihydroergotamine depended on which outcome measure was of greatest interest. | 2345-2559 | 2,345 | 2,559 | A retrospective pharmacoeconomic model suggested that the cost-effectiveness of subcutaneous @SUBJECT$ @PREDICAT$ subcutaneous @OBJECT$ depended on which outcome measure was of greatest interest. |
Possible | preserve | 180-191 | 180-191 | T13 | accompanied | COEXISTS_WITH | 180 | 191 | preserve | 195-206 | 195-206 | T10 | sensitivity | Finding | 195 | 206 | preserve | 63-71 | 63-71 | T4 | Migraine | DiseaseOrSyndrome | 63 | 71 | A16 | Migraine is a common illness characterised by severe, often throbbing and/or unilateral headache, which may be accompanied by sensitivity to light or noise. | 63-225 | 63 | 225 | @OBJECT$ is a common illness characterised by severe, often throbbing and/or unilateral headache, which may be @PREDICAT$ by @SUBJECT$ to light or noise. |
Fact | preserve | 1912-1931 | 1924-1931 | T111 | sumatriptan therapy | USES | 1,912 | 1,931 | preserve | 1924-1931 | 1924-1931 | T107 | therapy | TherapeuticOrPreventiveProcedure | 1,924 | 1,931 | preserve | 1912-1923 | 1912-1923 | T106 | sumatriptan | OrganicChemical | 1,912 | 1,923 | A18 | Data from studies of patients who used their usual therapies and sumatriptan in nonblinded, sequential phases indicate that both workplace and nonworkplace productivity losses were reduced during sumatriptan therapy. | 1698-1932 | 1,698 | 1,932 | Data from studies of patients who used their usual therapies and sumatriptan in nonblinded, sequential phases indicate that both workplace and nonworkplace productivity losses were reduced during @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1072-1079 | 1072-1079 | T68 | reduces | PREVENTS | 1,072 | 1,079 | preserve | 1054-1065 | 1054-1065 | T60 | Sumatriptan | OrganicChemical | 1,054 | 1,065 | preserve | 1080-1097 | 1089-1097 | T61 | headache severity | SignOrSymptom | 1,080 | 1,097 | A19 | Sumatriptan reduces headache severity within 2 hours of oral administration in 50 to 67% of patients and within 1 hour of subcutaneous administration in 70 to 80% of patients. | 1054-1247 | 1,054 | 1,247 | @SUBJECT$ @PREDICAT$ @OBJECT$ within 2 hours of oral administration in 50 to 67% of patients and within 1 hour of subcutaneous administration in 70 to 80% of patients. |
Fact | preserve | 2753-2761 | 2753-2761 | T168 | compared | compared_with | 2,753 | 2,761 | preserve | 2696-2707 | 2696-2707 | T151 | Sumatriptan | OrganicChemical | 2,696 | 2,707 | preserve | 2783-2790 | 2783-2790 | T156 | therapy | TherapeuticOrPreventiveProcedure | 2,783 | 2,790 | A21 | Sumatriptan improved global quality-of-life scores compared with patients' usual therapy in a randomised crossover trial and appeared to do the same when the drugs were administered in nonblinded, sequential phases in trials which used general and migraine-specific quality-of-life instruments. | 2696-3015 | 2,696 | 3,015 | @SUBJECT$ improved global quality-of-life scores @PREDICAT$ with patients' usual @OBJECT$ in a randomised crossover trial and appeared to do the same when the drugs were administered in nonblinded, sequential phases in trials which used general and migraine-specific quality-of-life instruments. |
Uncommitted | preserve | 1791-1793 | 1791-1793 | T108 | in | PROCESS_OF | 1,791 | 1,793 | preserve | 1745-1753 | 1745-1753 | T103 | ischemia | DiseaseOrSyndrome | 1,745 | 1,753 | preserve | 1794-1802 | 1794-1802 | T106 | patients | PatientOrDisabledGroup | 1,794 | 1,802 | A1 | Both groups were likely to evaluate their patients for ischemia and possible revascularization, even in patients not having angina. | 1684-1827 | 1,684 | 1,827 | Both groups were likely to evaluate their patients for @SUBJECT$ and possible revascularization, even @PREDICAT$ @OBJECT$ not having angina. |
Fact | preserve | 2104-2106 | 2104-2106 | T133 | in | TREATS | 2,104 | 2,106 | preserve | 2171-2190 | 2183-2190 | T132 | maintenance therapy | TherapeuticOrPreventiveProcedure | 2,171 | 2,190 | preserve | 2138-2140 | 2138-2140 | T131 | HF | DiseaseOrSyndrome | 2,138 | 2,140 | A2 | HF specialists more often used angiotensin-converting enzyme inhibitors as part of their initial therapy in patients with mild to moderate HF (94% vs 86%) and during maintenance therapy (91% vs 80%). | 1987-2204 | 1,987 | 2,204 | HF specialists more often used angiotensin-converting enzyme inhibitors as part of their initial therapy @PREDICAT$ patients with mild to moderate @OBJECT$ (94% vs 86%) and during @SUBJECT$ (91% vs 80%). |
Fact | preserve | 2104-2106 | 2104-2106 | T133 | in | TREATS | 2,104 | 2,106 | preserve | 2096-2103 | 2096-2103 | T128 | therapy | TherapeuticOrPreventiveProcedure | 2,096 | 2,103 | preserve | 2138-2140 | 2138-2140 | T131 | HF | DiseaseOrSyndrome | 2,138 | 2,140 | A4 | HF specialists more often used angiotensin-converting enzyme inhibitors as part of their initial therapy in patients with mild to moderate HF (94% vs 86%) and during maintenance therapy (91% vs 80%). | 1987-2204 | 1,987 | 2,204 | HF specialists more often used angiotensin-converting enzyme inhibitors as part of their initial @SUBJECT$ @PREDICAT$ patients with mild to moderate @OBJECT$ (94% vs 86%) and during maintenance therapy (91% vs 80%). |
Fact | preserve | 783-785 | 783-785 | T58 | in | TREATS | 783 | 785 | preserve | 763-772 | 763-772 | T44 | treatment | TherapeuticOrPreventiveProcedure | 763 | 772 | preserve | 806-808 | 806-808 | T46 | HF | DiseaseOrSyndrome | 806 | 808 | A7 | METHODS: A survey examining diagnostic and treatment practices in patients with HF was sent to a sample of cardiologists derived from the American Medical Association Masterfile and to HF specialists who were members of the Society of Transplant Cardiologists or principal investigators in HF trials. | 720-1038 | 720 | 1,038 | METHODS: A survey examining diagnostic and @SUBJECT$ practices @PREDICAT$ patients with @OBJECT$ was sent to a sample of cardiologists derived from the American Medical Association Masterfile and to HF specialists who were members of the Society of Transplant Cardiologists or principal investigators in HF trials. |
Fact | preserve | 705-709 | 705-709 | T40 | with | PROCESS_OF | 705 | 709 | preserve | 716-718 | 716-718 | T37 | HF | DiseaseOrSyndrome | 716 | 718 | preserve | 696-704 | 696-704 | T36 | patients | PatientOrDisabledGroup | 696 | 704 | A10 | OBJECTIVES: This study was designed to identify differences in HF management practices between general cardiologists and cardiologists specializing in the treatment of patients with HF. | 516-719 | 516 | 719 | OBJECTIVES: This study was designed to identify differences in HF management practices between general cardiologists and cardiologists specializing in the treatment of @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 2104-2106 | 2104-2106 | T133 | in | TREATS | 2,104 | 2,106 | preserve | 2096-2103 | 2096-2103 | T128 | therapy | TherapeuticOrPreventiveProcedure | 2,096 | 2,103 | preserve | 2107-2115 | 2107-2115 | T129 | patients | PatientOrDisabledGroup | 2,107 | 2,115 | A11 | HF specialists more often used angiotensin-converting enzyme inhibitors as part of their initial therapy in patients with mild to moderate HF (94% vs 86%) and during maintenance therapy (91% vs 80%). | 1987-2204 | 1,987 | 2,204 | HF specialists more often used angiotensin-converting enzyme inhibitors as part of their initial @SUBJECT$ @PREDICAT$ @OBJECT$ with mild to moderate HF (94% vs 86%) and during maintenance therapy (91% vs 80%). |
Fact | preserve | 801-805 | 801-805 | T59 | with | PROCESS_OF | 801 | 805 | preserve | 806-808 | 806-808 | T46 | HF | DiseaseOrSyndrome | 806 | 808 | preserve | 786-794 | 786-794 | T45 | patients | PatientOrDisabledGroup | 786 | 794 | A13 | METHODS: A survey examining diagnostic and treatment practices in patients with HF was sent to a sample of cardiologists derived from the American Medical Association Masterfile and to HF specialists who were members of the Society of Transplant Cardiologists or principal investigators in HF trials. | 720-1038 | 720 | 1,038 | METHODS: A survey examining diagnostic and treatment practices in @OBJECT$ @PREDICAT$ @SUBJECT$ was sent to a sample of cardiologists derived from the American Medical Association Masterfile and to HF specialists who were members of the Society of Transplant Cardiologists or principal investigators in HF trials. |
Fact | preserve | 683-692 | 683-692 | T38 | treatment | TREATS | 683 | 692 | preserve | 649-662 | 649-662 | T34 | cardiologists | ProfessionalOrOccupationalGroup | 649 | 662 | preserve | 696-704 | 696-704 | T36 | patients | PatientOrDisabledGroup | 696 | 704 | A14 | OBJECTIVES: This study was designed to identify differences in HF management practices between general cardiologists and cardiologists specializing in the treatment of patients with HF. | 516-719 | 516 | 719 | OBJECTIVES: This study was designed to identify differences in HF management practices between general cardiologists and @SUBJECT$ specializing in the @PREDICAT$ of @OBJECT$ with HF. |
Fact | preserve | 2116-2120 | 2116-2120 | T135 | with | PROCESS_OF | 2,116 | 2,120 | preserve | 2138-2140 | 2138-2140 | T131 | HF | DiseaseOrSyndrome | 2,138 | 2,140 | preserve | 2107-2115 | 2107-2115 | T129 | patients | PatientOrDisabledGroup | 2,107 | 2,115 | A16 | HF specialists more often used angiotensin-converting enzyme inhibitors as part of their initial therapy in patients with mild to moderate HF (94% vs 86%) and during maintenance therapy (91% vs 80%). | 1987-2204 | 1,987 | 2,204 | HF specialists more often used angiotensin-converting enzyme inhibitors as part of their initial therapy in @OBJECT$ @PREDICAT$ mild to moderate @SUBJECT$ (94% vs 86%) and during maintenance therapy (91% vs 80%). |
Probable | preserve | 1648-1651 | 1648-1651 | T99 | use | ADMINISTERED_TO | 1,648 | 1,651 | preserve | 1655-1669 | 1655-1669 | T95 | echocardiogram | DiagnosticProcedure | 1,655 | 1,669 | preserve | 1609-1620 | 1609-1620 | T92 | specialists | ProfessionalOrOccupationalGroup | 1,609 | 1,620 | A19 | For instance, in patients being evaluated for the first time, cardiologists reported using a chest radiograph to assist in the diagnosis more than did HF specialists (47% vs 12%), whereas HF specialists were more likely to use an echocardiogram (73% vs 48%). | 1406-1683 | 1,406 | 1,683 | For instance, in patients being evaluated for the first time, cardiologists reported using a chest radiograph to assist in the diagnosis more than did HF specialists (47% vs 12%), whereas HF @OBJECT$ were more likely to @PREDICAT$ an @SUBJECT$ (73% vs 48%). |
Fact | preserve | 683-692 | 683-692 | T38 | treatment | TREATS | 683 | 692 | preserve | 631-644 | 631-644 | T33 | cardiologists | ProfessionalOrOccupationalGroup | 631 | 644 | preserve | 696-704 | 696-704 | T36 | patients | PatientOrDisabledGroup | 696 | 704 | A21 | OBJECTIVES: This study was designed to identify differences in HF management practices between general cardiologists and cardiologists specializing in the treatment of patients with HF. | 516-719 | 516 | 719 | OBJECTIVES: This study was designed to identify differences in HF management practices between general @SUBJECT$ and cardiologists specializing in the @PREDICAT$ of @OBJECT$ with HF. |
Probable | preserve | 2461-2467 | 2461-2467 | T154 | manage | TREATS | 2,461 | 2,467 | preserve | 2439-2450 | 2439-2450 | T149 | specialists | ProfessionalOrOccupationalGroup | 2,439 | 2,450 | preserve | 2474-2482 | 2474-2482 | T150 | patients | PatientOrDisabledGroup | 2,474 | 2,482 | A22 | CONCLUSION: Cardiologists and HF specialists generally manage their patients in conformity with guidelines. | 2400-2519 | 2,400 | 2,519 | CONCLUSION: Cardiologists and HF @SUBJECT$ generally @PREDICAT$ their @OBJECT$ in conformity with guidelines. |
Probable | preserve | 2461-2467 | 2461-2467 | T154 | manage | TREATS | 2,461 | 2,467 | preserve | 2418-2431 | 2418-2431 | T147 | Cardiologists | ProfessionalOrOccupationalGroup | 2,418 | 2,431 | preserve | 2474-2482 | 2474-2482 | T150 | patients | PatientOrDisabledGroup | 2,474 | 2,482 | A23 | CONCLUSION: Cardiologists and HF specialists generally manage their patients in conformity with guidelines. | 2400-2519 | 2,400 | 2,519 | CONCLUSION: @SUBJECT$ and HF specialists generally @PREDICAT$ their @OBJECT$ in conformity with guidelines. |
Fact | preserve | 783-785 | 783-785 | T58 | in | TREATS | 783 | 785 | preserve | 763-772 | 763-772 | T44 | treatment | TherapeuticOrPreventiveProcedure | 763 | 772 | preserve | 786-794 | 786-794 | T45 | patients | PatientOrDisabledGroup | 786 | 794 | A25 | METHODS: A survey examining diagnostic and treatment practices in patients with HF was sent to a sample of cardiologists derived from the American Medical Association Masterfile and to HF specialists who were members of the Society of Transplant Cardiologists or principal investigators in HF trials. | 720-1038 | 720 | 1,038 | METHODS: A survey examining diagnostic and @SUBJECT$ practices @PREDICAT$ @OBJECT$ with HF was sent to a sample of cardiologists derived from the American Medical Association Masterfile and to HF specialists who were members of the Society of Transplant Cardiologists or principal investigators in HF trials. |
Fact | preserve | 2104-2106 | 2104-2106 | T133 | in | TREATS | 2,104 | 2,106 | preserve | 2171-2190 | 2183-2190 | T132 | maintenance therapy | TherapeuticOrPreventiveProcedure | 2,171 | 2,190 | preserve | 2107-2115 | 2107-2115 | T129 | patients | PatientOrDisabledGroup | 2,107 | 2,115 | A26 | HF specialists more often used angiotensin-converting enzyme inhibitors as part of their initial therapy in patients with mild to moderate HF (94% vs 86%) and during maintenance therapy (91% vs 80%). | 1987-2204 | 1,987 | 2,204 | HF specialists more often used angiotensin-converting enzyme inhibitors as part of their initial therapy @PREDICAT$ @OBJECT$ with mild to moderate HF (94% vs 86%) and during @SUBJECT$ (91% vs 80%). |
Fact | preserve | 2211-2213 | 2211-2213 | T136 | in | PROCESS_OF | 2,211 | 2,213 | preserve | 2198-2210 | 2198-2210 | T130 | hypertension | DiseaseOrSyndrome | 2,198 | 2,210 | preserve | 2234-2238 | 2234-2238 | T132 | rats | Mammal | 2,234 | 2,238 | A2 | In summary, selective ET(A) but not ET(A)/ET(B) receptor blockade can prevent the aggravation of hypertension in renal failure rats treated with rhEPO. | 2095-2258 | 2,095 | 2,258 | In summary, selective ET(A) but not ET(A)/ET(B) receptor blockade can prevent the aggravation of @SUBJECT$ @PREDICAT$ renal failure @OBJECT$ treated with rhEPO. |
Fact | preserve | 766-774 | 766-774 | T57 | received | ADMINISTERED_TO | 766 | 774 | preserve | 788-793 | 788-793 | T52 | rhEPO | AminoAcidPeptideOrProtein | 788 | 793 | preserve | 758-765 | 758-765 | T50 | animals | Animal | 758 | 765 | A3 | After a 4-wk stabilization period, the animals received either rhEPO (100 U/kg, subcutaneously, three times per week) or the vehicle for 4 wk. | 719-867 | 719 | 867 | After a 4-wk stabilization period, the @OBJECT$ @PREDICAT$ either @SUBJECT$ (100 U/kg, subcutaneously, three times per week) or the vehicle for 4 wk. |
Fact | preserve | 2220-2238 | 2234-2238 | T135 | renal failure rats | PROCESS_OF | 2,220 | 2,238 | preserve | 2220-2233 | 2226-2233 | T131 | renal failure | DiseaseOrSyndrome | 2,220 | 2,233 | preserve | 2234-2238 | 2234-2238 | T132 | rats | Mammal | 2,234 | 2,238 | A4 | In summary, selective ET(A) but not ET(A)/ET(B) receptor blockade can prevent the aggravation of hypertension in renal failure rats treated with rhEPO. | 2095-2258 | 2,095 | 2,258 | In summary, selective ET(A) but not ET(A)/ET(B) receptor blockade can prevent the aggravation of hypertension in @SUBJECT$ @PREDICAT$ @OBJECT$ treated with rhEPO. |
Fact | preserve | 2252-2257 | 2252-2257 | T138 | rhEPO | PART_OF | 2,252 | 2,257 | preserve | 2252-2257 | 2252-2257 | T134 | rhEPO | AminoAcidPeptideOrProtein | 2,252 | 2,257 | preserve | 2252-2257 | 2252-2257 | T134 | rhEPO | AminoAcidPeptideOrProtein | 2,252 | 2,257 | A6 | In summary, selective ET(A) but not ET(A)/ET(B) receptor blockade can prevent the aggravation of hypertension in renal failure rats treated with rhEPO. | 2095-2258 | 2,095 | 2,258 | In summary, selective ET(A) but not ET(A)/ET(B) receptor blockade can prevent the aggravation of hypertension in renal failure rats treated with @OBJECT$ @SUBJECT$ @PREDICAT$ . |
Fact | preserve | 611-618 | 611-618 | T44 | induced | CAUSES | 611 | 618 | preserve | 644-655 | 644-655 | T39 | nephrectomy | TherapeuticOrPreventiveProcedure | 644 | 655 | preserve | 593-606 | 599-606 | T36 | Renal failure | DiseaseOrSyndrome | 593 | 606 | A7 | Renal failure was induced by a two-stage 5/6 nephrectomy; the animals developed uremia, anemia, and hypertension. | 593-718 | 593 | 718 | @OBJECT$ was @PREDICAT$ by a two-stage 5/6 @SUBJECT$ ; the animals developed uremia, anemia, and hypertension. |
Fact | preserve | 1765-1767 | 1765-1767 | T105 | in | PROCESS_OF | 1,765 | 1,767 | preserve | 1752-1764 | 1752-1764 | T103 | hypertension | DiseaseOrSyndrome | 1,752 | 1,764 | preserve | 1775-1779 | 1775-1779 | T104 | rats | Mammal | 1,775 | 1,779 | A8 | Both ET-1 receptor antagonists bosentan and LU135252 were effective in attenuating the progression of hypertension in uremic rats receiving the vehicle (P < 0.05). | 1644-1819 | 1,644 | 1,819 | Both ET-1 receptor antagonists bosentan and LU135252 were effective in attenuating the progression of @SUBJECT$ @PREDICAT$ uremic @OBJECT$ receiving the vehicle (P < 0.05). |
Fact | preserve | 669-678 | 669-678 | T45 | developed | PROCESS_OF | 669 | 678 | preserve | 705-717 | 705-717 | T43 | hypertension | DiseaseOrSyndrome | 705 | 717 | preserve | 661-668 | 661-668 | T40 | animals | Animal | 661 | 668 | A9 | Renal failure was induced by a two-stage 5/6 nephrectomy; the animals developed uremia, anemia, and hypertension. | 593-718 | 593 | 718 | Renal failure was induced by a two-stage 5/6 nephrectomy; the @OBJECT$ @PREDICAT$ uremia, anemia, and @SUBJECT$ . |
Fact | preserve | 274-300 | 286-300 | T18 | human erythropoietin | PART_OF | 274 | 300 | preserve | 262-300 | 286-300 | T15 | recombinant human erythropoietin | AminoAcidPeptideOrProtein | 262 | 300 | preserve | 274-279 | 274-279 | T14 | human | Human | 274 | 279 | A10 | Recently, it was reported that blood vessel immunoreactive endothelin-1 (irET-1) content is increased in hypertensive uremic rats treated with recombinant human erythropoietin (rhEPO). | 112-309 | 112 | 309 | Recently, it was reported that blood vessel immunoreactive endothelin-1 (irET-1) content is increased in hypertensive uremic rats treated with @SUBJECT$ @OBJECT$ @PREDICAT$ (rhEPO). |
Fact | preserve | 1873-1875 | 1873-1875 | T115 | in | TREATS | 1,873 | 1,875 | preserve | 1820-1829 | 1820-1829 | T106 | Treatment | TherapeuticOrPreventiveProcedure | 1,820 | 1,829 | preserve | 1896-1900 | 1896-1900 | T112 | rats | Mammal | 1,896 | 1,900 | A11 | Treatment with LU135252 corrected the increase in BP in rhEPO-treated rats (160+/-7 mmHg versus 187+/-9 mmHg, P < 0.05). | 1820-1946 | 1,820 | 1,946 | @SUBJECT$ with LU135252 corrected the increase in BP @PREDICAT$ rhEPO-treated @OBJECT$ (160+/-7 mmHg versus 187+/-9 mmHg, P < 0.05). |
Fact | preserve | 462-471 | 462-471 | T34 | receiving | ADMINISTERED_TO | 462 | 471 | preserve | 472-477 | 472-477 | T28 | rhEPO | AminoAcidPeptideOrProtein | 472 | 477 | preserve | 457-461 | 457-461 | T26 | rats | Mammal | 457 | 461 | A12 | The present study was designed to evaluate whether ET-1 receptor blockade can prevent the progression of hypertension in renal failure rats receiving rhEPO and, if so, whether selective ET(A) and nonselective ET(A)/ET(B) receptor antagonists are equally effective. | 310-592 | 310 | 592 | The present study was designed to evaluate whether ET-1 receptor blockade can prevent the progression of hypertension in renal failure @OBJECT$ @PREDICAT$ @SUBJECT$ and, if so, whether selective ET(A) and nonselective ET(A)/ET(B) receptor antagonists are equally effective. |
Fact | preserve | 434-436 | 434-436 | T33 | in | PROCESS_OF | 434 | 436 | preserve | 421-433 | 421-433 | T24 | hypertension | DiseaseOrSyndrome | 421 | 433 | preserve | 457-461 | 457-461 | T26 | rats | Mammal | 457 | 461 | A13 | The present study was designed to evaluate whether ET-1 receptor blockade can prevent the progression of hypertension in renal failure rats receiving rhEPO and, if so, whether selective ET(A) and nonselective ET(A)/ET(B) receptor antagonists are equally effective. | 310-592 | 310 | 592 | The present study was designed to evaluate whether ET-1 receptor blockade can prevent the progression of @SUBJECT$ @PREDICAT$ renal failure @OBJECT$ receiving rhEPO and, if so, whether selective ET(A) and nonselective ET(A)/ET(B) receptor antagonists are equally effective. |
Fact | preserve | 221-223 | 221-223 | T16 | in | LOCATION_OF | 221 | 223 | preserve | 244-248 | 244-248 | T13 | rats | Mammal | 244 | 248 | preserve | 171-183 | 171-183 | T11 | endothelin-1 | AminoAcidPeptideOrProtein | 171 | 183 | A14 | Recently, it was reported that blood vessel immunoreactive endothelin-1 (irET-1) content is increased in hypertensive uremic rats treated with recombinant human erythropoietin (rhEPO). | 112-309 | 112 | 309 | Recently, it was reported that blood vessel immunoreactive @OBJECT$ (irET-1) content is increased @PREDICAT$ hypertensive uremic @SUBJECT$ treated with recombinant human erythropoietin (rhEPO). |
Fact | preserve | 2239-2246 | 2239-2246 | T137 | treated | TREATS | 2,239 | 2,246 | preserve | 2252-2257 | 2252-2257 | T134 | rhEPO | AminoAcidPeptideOrProtein | 2,252 | 2,257 | preserve | 2234-2238 | 2234-2238 | T132 | rats | Mammal | 2,234 | 2,238 | A15 | In summary, selective ET(A) but not ET(A)/ET(B) receptor blockade can prevent the aggravation of hypertension in renal failure rats treated with rhEPO. | 2095-2258 | 2,095 | 2,258 | In summary, selective ET(A) but not ET(A)/ET(B) receptor blockade can prevent the aggravation of hypertension in renal failure @OBJECT$ @PREDICAT$ with @SUBJECT$ . |
Fact | preserve | 2025-2027 | 2025-2027 | T127 | in | PROCESS_OF | 2,025 | 2,027 | preserve | 2012-2024 | 2012-2024 | T119 | hypertension | DiseaseOrSyndrome | 2,012 | 2,024 | preserve | 2042-2046 | 2042-2046 | T123 | rats | Mammal | 2,042 | 2,046 | A16 | In contrast, bosentan did not attenuate the progression of hypertension in rhEPO-treated rats (172+/-10 mmHg versus 168+/-9 mmHg, NS). | 1947-2094 | 1,947 | 2,094 | In contrast, bosentan did not attenuate the progression of @SUBJECT$ @PREDICAT$ rhEPO-treated @OBJECT$ (172+/-10 mmHg versus 168+/-9 mmHg, NS). |
Fact | preserve | 669-678 | 669-678 | T45 | developed | PROCESS_OF | 669 | 678 | preserve | 687-693 | 687-693 | T42 | anemia | DiseaseOrSyndrome | 687 | 693 | preserve | 661-668 | 661-668 | T40 | animals | Animal | 661 | 668 | A17 | Renal failure was induced by a two-stage 5/6 nephrectomy; the animals developed uremia, anemia, and hypertension. | 593-718 | 593 | 718 | Renal failure was induced by a two-stage 5/6 nephrectomy; the @OBJECT$ @PREDICAT$ uremia, @SUBJECT$ , and hypertension. |
Fact | preserve | 94-96 | 94-96 | T8 | in | COEXISTS_WITH | 94 | 96 | preserve | 81-93 | 81-93 | T6 | hypertension | DiseaseOrSyndrome | 81 | 93 | preserve | 97-110 | 103-110 | T7 | renal failure | DiseaseOrSyndrome | 97 | 110 | A19 | Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure. | 0-111 | 0 | 111 | Differential effects of endothelin-1 antagonists on erythropoietin-induced @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Possible | preserve | 2322-2330 | 2322-2330 | T152 | involved | ASSOCIATED_WITH | 2,322 | 2,330 | preserve | 2290-2300 | 2290-2300 | T142 | endothelin | AminoAcidPeptideOrProtein | 2,290 | 2,300 | preserve | 2338-2350 | 2338-2350 | T144 | pathogenesis | PathologicFunction | 2,338 | 2,350 | A20 | These results suggest that the endothelin system may be involved in the pathogenesis of rhEPO-induced hypertension in uremic rats with a differential role for ET(A) and ET(B) receptors. | 2259-2457 | 2,259 | 2,457 | These results suggest that the @SUBJECT$ system may be @PREDICAT$ in the @OBJECT$ of rhEPO-induced hypertension in uremic rats with a differential role for ET(A) and ET(B) receptors. |
Fact | preserve | 249-256 | 249-256 | T17 | treated | TREATS | 249 | 256 | preserve | 262-300 | 286-300 | T15 | recombinant human erythropoietin | AminoAcidPeptideOrProtein | 262 | 300 | preserve | 244-248 | 244-248 | T13 | rats | Mammal | 244 | 248 | A21 | Recently, it was reported that blood vessel immunoreactive endothelin-1 (irET-1) content is increased in hypertensive uremic rats treated with recombinant human erythropoietin (rhEPO). | 112-309 | 112 | 309 | Recently, it was reported that blood vessel immunoreactive endothelin-1 (irET-1) content is increased in hypertensive uremic @OBJECT$ @PREDICAT$ with @SUBJECT$ (rhEPO). |
Fact | preserve | 2239-2246 | 2239-2246 | T137 | treated | TREATS | 2,239 | 2,246 | preserve | 2252-2257 | 2252-2257 | T134 | rhEPO | AminoAcidPeptideOrProtein | 2,252 | 2,257 | preserve | 2220-2233 | 2226-2233 | T131 | renal failure | DiseaseOrSyndrome | 2,220 | 2,233 | A22 | In summary, selective ET(A) but not ET(A)/ET(B) receptor blockade can prevent the aggravation of hypertension in renal failure rats treated with rhEPO. | 2095-2258 | 2,095 | 2,258 | In summary, selective ET(A) but not ET(A)/ET(B) receptor blockade can prevent the aggravation of hypertension in @OBJECT$ rats @PREDICAT$ with @SUBJECT$ . |
Fact | preserve | 669-678 | 669-678 | T45 | developed | PROCESS_OF | 669 | 678 | preserve | 679-685 | 679-685 | T41 | uremia | DiseaseOrSyndrome | 679 | 685 | preserve | 661-668 | 661-668 | T40 | animals | Animal | 661 | 668 | A24 | Renal failure was induced by a two-stage 5/6 nephrectomy; the animals developed uremia, anemia, and hypertension. | 593-718 | 593 | 718 | Renal failure was induced by a two-stage 5/6 nephrectomy; the @OBJECT$ @PREDICAT$ @SUBJECT$ , anemia, and hypertension. |
Fact | preserve | 437-461 | 457-461 | T32 | renal failure rats | PROCESS_OF | 437 | 461 | preserve | 437-450 | 443-450 | T25 | renal failure | DiseaseOrSyndrome | 437 | 450 | preserve | 457-461 | 457-461 | T26 | rats | Mammal | 457 | 461 | A25 | The present study was designed to evaluate whether ET-1 receptor blockade can prevent the progression of hypertension in renal failure rats receiving rhEPO and, if so, whether selective ET(A) and nonselective ET(A)/ET(B) receptor antagonists are equally effective. | 310-592 | 310 | 592 | The present study was designed to evaluate whether ET-1 receptor blockade can prevent the progression of hypertension in @SUBJECT$ @PREDICAT$ @OBJECT$ receiving rhEPO and, if so, whether selective ET(A) and nonselective ET(A)/ET(B) receptor antagonists are equally effective. |
Counterfact | preserve | 1983-1992 | 1983-1992 | T126 | attenuate | TREATS | 1,983 | 1,992 | preserve | 1966-1974 | 1966-1974 | T116 | bosentan | OrganicChemical | 1,966 | 1,974 | preserve | 2012-2024 | 2012-2024 | T119 | hypertension | DiseaseOrSyndrome | 2,012 | 2,024 | A26 | In contrast, bosentan did not attenuate the progression of hypertension in rhEPO-treated rats (172+/-10 mmHg versus 168+/-9 mmHg, NS). | 1947-2094 | 1,947 | 2,094 | In contrast, @SUBJECT$ did not @PREDICAT$ the progression of @OBJECT$ in rhEPO-treated rats (172+/-10 mmHg versus 168+/-9 mmHg, NS). |
Fact | preserve | 1950-1954 | 1950-1954 | T118 | with | PROCESS_OF | 1,950 | 1,954 | preserve | 1961-1973 | 1961-1973 | T113 | hypertension | DiseaseOrSyndrome | 1,961 | 1,973 | preserve | 1942-1949 | 1942-1949 | T112 | animals | Animal | 1,942 | 1,949 | A1 | These data indicate that the chronic depressor actions of metformin are enhanced in animals with hypertension exacerbated by a high-salt diet. | 1852-2006 | 1,852 | 2,006 | These data indicate that the chronic depressor actions of metformin are enhanced in @OBJECT$ @PREDICAT$ @SUBJECT$ exacerbated by a high-salt diet. |
Fact | preserve | 203-205 | 203-205 | T17 | in | PROCESS_OF | 203 | 205 | preserve | 188-202 | 194-202 | T13 | blood pressure | Finding | 188 | 202 | preserve | 206-212 | 206-212 | T14 | humans | Human | 206 | 212 | A5 | Metformin, an antihyperglycemic agent used for treatment of type 2 diabetes mellitus, lowers blood pressure in humans and experimental animals. | 89-238 | 89 | 238 | Metformin, an antihyperglycemic agent used for treatment of type 2 diabetes mellitus, lowers @SUBJECT$ @PREDICAT$ @OBJECT$ and experimental animals. |
Fact | preserve | 1170-1184 | 1175-1184 | T72 | drug treatment | USES | 1,170 | 1,184 | preserve | 1175-1184 | 1175-1184 | T63 | treatment | TherapeuticOrPreventiveProcedure | 1,175 | 1,184 | preserve | 1170-1174 | 1170-1174 | T62 | drug | PharmacologicSubstance | 1,170 | 1,174 | A6 | Although metformin did not affect blood pressure in the animals that ate the normal-salt diet (vehicle, 130+/-3 mm Hg; metformin, 133+/-5 mm Hg; mean+/-SEM), drug treatment blunted the rise in pressure caused by a high-salt diet (vehicle, 153+/-4 mm Hg; metformin, 140+/-5 mm Hg; P<0.001). | 1000-1314 | 1,000 | 1,314 | Although metformin did not affect blood pressure in the animals that ate the normal-salt diet (vehicle, 130+/-3 mm Hg; metformin, 133+/-5 mm Hg; mean+/-SEM), @OBJECT$ @PREDICAT$ @SUBJECT$ blunted the rise in pressure caused by a high-salt diet (vehicle, 153+/-4 mm Hg; metformin, 140+/-5 mm Hg; P<0.001). |
Counterfact | preserve | 1033-1039 | 1033-1039 | T71 | affect | AFFECTS | 1,033 | 1,039 | preserve | 1009-1018 | 1009-1018 | T52 | metformin | OrganicChemical | 1,009 | 1,018 | preserve | 1040-1054 | 1046-1054 | T54 | blood pressure | Finding | 1,040 | 1,054 | A7 | Although metformin did not affect blood pressure in the animals that ate the normal-salt diet (vehicle, 130+/-3 mm Hg; metformin, 133+/-5 mm Hg; mean+/-SEM), drug treatment blunted the rise in pressure caused by a high-salt diet (vehicle, 153+/-4 mm Hg; metformin, 140+/-5 mm Hg; P<0.001). | 1000-1314 | 1,000 | 1,314 | Although @SUBJECT$ did not @PREDICAT$ @OBJECT$ in the animals that ate the normal-salt diet (vehicle, 130+/-3 mm Hg; metformin, 133+/-5 mm Hg; mean+/-SEM), drug treatment blunted the rise in pressure caused by a high-salt diet (vehicle, 153+/-4 mm Hg; metformin, 140+/-5 mm Hg; P<0.001). |
Fact | preserve | 47-49 | 47-49 | T7 | in | PROCESS_OF | 47 | 49 | preserve | 34-46 | 34-46 | T4 | hypertension | DiseaseOrSyndrome | 34 | 46 | preserve | 50-87 | 83-87 | T5 | spontaneously hypertensive rats | Mammal | 50 | 87 | A8 | Metformin attenuates salt-induced hypertension in spontaneously hypertensive rats. | 0-88 | 0 | 88 | Metformin attenuates salt-induced @SUBJECT$ @PREDICAT$ @OBJECT$ . |